Philippe holds a PhD in Pharmacology of Anticancer Drugs from the University of Bourgogne, obtained in 1992. He began his professional career as a project leader at Debiopharm from 1992 to 1998. In 1995, Philippe founded Oncodesign Biotechnology SA in Dijon, marking the start of his journey as a serial entrepreneur in the life sciences sector. From 1995 to 2022, as Chairman and CEO, he spearheaded the creation and development of Oncodesign, ultimately transforming it into two independent companies: Oncodesign Services (ODS) and Oncodesign Precision Medicine (OPM). Since 2022, he has been the Chairman, CEO, and main investor of OPM.
Philippe is renowned for his comprehensive expertise across the life sciences value chain. In 2012, he founded the French Association of Life Sciences Service and Innovation Companies (AFSSI), further solidifying his influence in the field. He also serves on the boards of several academic institutions, Contract Research Organizations (CROs), and biotech companies.
His extensive experience and visionary leadership have been pivotal in driving innovation and growth in the life sciences industry. Philippe’s strategic insight and entrepreneurial spirit make him an invaluable asset to the ANS board, contributing significantly to advancing pharmaceutical and biotechnology innovation.